Covid-19 research with humans in Brazil

Castro-Silva, Igor Iuco; Maciel, Jacques Antonio Cavalcante

doi:10.1590/1983-80422020284429

Acessibilidade / Reportar erro

Brasil

Español English

sumário « anterior atual seguinte »

Sumário

Research • Rev. Bioét. 28 (4) • Oct-Dec 2020 • https://doi.org/10.1590/1983-80422020284429 copy

Covid-19 research with humans in Brazil

Authorship SCIMAGO INSTITUTIONS RANKINGS

Abstract

The Covid-19 pandemic challenges research institutions with the urgent need of responding to the morbidity and mortality caused by the virus. This study aimed to overview studies with humans on this disease in the first three months of 2020, in Brazil. Official data of the population and research protocols on Covid-19, distributed by Brazilian states, supported this temporal analysis. The incidence of the virus has grown exponentially, especially in the North and Northeast regions. Despite the discrete, slow, and asymmetric diffusion of studies, they are concentrated in the Southeast, and few clinical trials have entered Phase II. The geographical distribution of research ethics committees, higher education institutions, investments in science and technology, health centers and hospitals generate state vulnerabilities when addressing the disease. Close longitudinal follow-up should be carried out in the face of regional inequities, to defend bioethical principles and human life.

Keywords:
Coronavirus; Sars virus; Bioethics; Human experimentation; Clinical trial

	Covid-19 incidence coefficient^* * FU: Federation unit; *Population base: 100,000 inhabitants.			Research protocols			Approved clinical trials
FU	T1	T2	T3	T1	T2	T3	T1	T2	T3
RO	0.16	13.46	175.89	–	–	–	–	–	–
AC	1.27	26.19	519.26	–	1	2	–	–	1
AM	0.75	68.11	714.16	1	5	6	1	3	3
RR	0.37	54.31	459.69	–	–	–	–	–	–
PA	0.06	14.68	302.21	–	1	2	–	–	1
AP	0.12	65.01	781.10	–	–	–	–	–	–
TO	0.31	2.31	168.57	–	–	–	–	–	–
MA	0.03	24.67	319.98	–	–	–	–	–	–
PI	0.19	6.71	109.77	–	–	2	–	–	–
CE	1.78	50.10	394.24	–	1	7	–	1	1
RN	0.36	19.68	132.26	–	–	3	–	–	–
PB	0.05	8.42	195.61	–	2	5	–	–	–
PE	0.44	36.46	293.93	–	3	9	–	–	–
AL	0.20	9.47	195.40	–	1	3	–	–	–
SE	0.43	5.27	231.61	–	3	3	–	–	–
BA	0.41	11.52	91.50	–	8	18	–	–	–
MG	0.60	6.10	32.45	–	13	29	–	2	4
ES	0.70	32.93	250.44	–	–	1	–	–	–
RJ	1.37	36.42	231.89	–	17	32	–	7	7
SP	1.62	36.34	181.54	4	89	150	1	18	32
PR	0.49	9.38	28.87	–	9	16	–	1	3
SC	0.94	15.35	94.62	–	2	5	–	–	–
RS	0.75	8.71	57.45	–	15	37	–	–	8
MS	0.75	6.64	36.53	–	1	2	–	–	–
MT	0.06	6.40	43.41	–	1	1	–	1	1
GO	0.33	6.46	35.80	–	2	4	–	–	–
DF	4.13	29.88	215.01	–	3	10	–	1	3
Brazil	0.89	23.34	176.77	5	177	347	2	34	64

	Category 1 - Research and innovation			Category 2 - Research and assistance
FU	Research ethics committees	Higher Education Institution	S&T investment coefficient (R$)^* * FU: Federation unit; *Population base: 100,000 inhabitants; S&T: science and technology	Public testing laboratories	Family Health Teams	Reference public hospitals
RO	12	36	5.34 mi	1	355	2
AC	3	14	9.17 mi	1	183	1
AM	15	33	4.00 mi	1	692	6
RR	4	10	5.70 mi	1	134	2
PA	21	89	2.21 mi	2	1,494	11
AP	3	16	0.68 mi	1	180	1
TO	10	33	3.65 mi	1	519	1
MA	9	65	2.18 mi	1	2,082	2
PI	12	52	2.52 mi	1	1,297	1
CE	39	117	3.88 mi	1	2,530	1
RN	6	34	6.19 mi	1	1,018	2
PB	16	54	6.56 mi	1	1,453	2
PE	32	145	3.01 mi	1	2,300	2
AL	5	36	0.88 mi	1	897	1
SE	4	26	3.63 mi	1	651	1
BA	49	179	4.13 mi	1	3,810	1
MG	96	370	5.29 mi	1	5,597	1
ES	15	85	4.35 mi	1	780	2
RJ	69	167	7.81 mi	2	2,295	1
SP	204	696	25.76 mi	1	5,241	1
PR	57	225	11.27 mi	1	2,327	7
SC	37	124	8.10 mi	1	1,825	2
RS	60	148	4.16 mi	1	1,929	2
MS	6	46	5.42 mi	1	629	1
MT	13	71	7.75 mi	1	730	1
GO	26	134	4.40 mi	1	1,541	2
DF	23	95	11.32 mi	1	454	1
Brazil	846	3,100	9.77 mi	29	42,943	58

Conselho Federal de Medicina SGAS 915, lote 72, CEP 70390-150, Tel.: (55 61) 3445-5932, Fax: (55 61) 3346-7384 - Brasília - DF - Brazil
E-mail: bioetica@portalmedico.org.br

Acompanhe os números deste periódico no seu leitor de RSS

[1] The authors declare no conflict of interest.